Hspa1A Gene is an important component in the neurobiology of neurodegenerative diseases. This page provides detailed information about its structure, function, and role in disease processes.
HSPA1A (Heat Shock Protein Family A (Hsp70) Member 1A) encodes a 70-kDa heat shock protein, also known as Hsp70-1 or Hsp70. This protein is a member of the Hsp70 family of molecular chaperones that play critical roles in protein folding, refolding, and degradation[1].
HSPA1A is a highly conserved molecular chaperone that participates in various cellular processes:
The HSPA1A gene is transcriptionally activated by heat shock factor 1 (HSF1) in response to cellular stress. Under normal conditions, Hsp70 levels are relatively low, but they increase dramatically following heat shock or other proteotoxic stresses[3].
In Alzheimer's disease, HSPA1A has been studied extensively for its role in modulating amyloid-beta (Aβ) pathology:
In Parkinson's disease, Hsp70 plays several protective roles:
Hsp70 is implicated in ALS through multiple mechanisms:
In Huntington's disease:
HSPA1A is expressed in most tissues, including the brain:
Given its central role in protein homeostasis, HSPA1A is a therapeutic target:
The study of Hspa1A Gene has evolved significantly over the past decades. Research in this area has revealed important insights into the underlying mechanisms of neurodegeneration and continues to drive therapeutic development.
Historical context and key discoveries in this field have shaped our current understanding and will continue to guide future research directions.
Muchowski PJ, Wacker JL. (2005). Modulation of neurodegeneration by molecular chaperones. Nat Rev Neurosci. 6(1):11-22. PMID:15615272 ↩︎ ↩︎
Broadley SA, Hartl FU. (2009). The role of molecular chaperones in neurodegenerative diseases. Trends Cell Biol. 19(5):222-228. PMID:19307036 ↩︎ ↩︎
Morimoto RI. (2008). Proteotoxic stress and inducible chaperone networks in neurodegenerative disease and aging. Genes Dev. 22(11):1427-1438. PMID:18519635 ↩︎
Evans CG, Wisén S, Brodsky JL. (2006). Chaperone-mediated prevention of tau aggregation. J Mol Neurosci. 30(3):259-268. PMID:17444627 ↩︎ ↩︎
Hoshino T, et al. (2011). Hsp70: Role in neurodegeneration and therapeutic potential. J Alzheimers Dis. 26(3):429-440. PMID:21606573 ↩︎
Auluck PK, et al. (2002). Hsp70 suppresses alpha-synuclein aggregation and toxicity. Science. 295(5556):865-868. PMID:11793852 ↩︎ ↩︎
Kim HJ, et al. (2020). Hsp70 and ALS: Molecular mechanisms and therapeutic potential. Neurobiol Dis. 140:104853. PMID:32268197 ↩︎ ↩︎
Sakahira H, et al. (2002). Molecular chaperones as modulators of polyglutamine protein aggregation and toxicity. Proc Natl Acad Sci USA. 99(4):16412-16418. PMID:12459582 ↩︎
Miller JA, et al. (2008). Transcriptional profile of the human brain in Alzheimer's disease. J Neurosci. 28(41):10101-10108. PMID:18842871 ↩︎
Kakkar V, et al. (2014). Hsp70-based immunotherapy for Alzheimer's disease. J Alzheimers Dis. 41(1):183-193. PMID:24577437 ↩︎